Mr. Samuel V. Alworth is the CEO and co-founder at AcuraStem. AcuraStem is pioneering patient-based therapeutics in the field of neurodegeneration. Mr. Alworth has over 20 years of broad experience in the life sciences covering research, drug development and business development. Since co-founding AcuraStem in 2016, he has been actively advancing drug candidates for ALS and FTD. With a technical background in the application of artificial intelligence and machine learning technologies to life science assay platforms, Mr. Alworth led the implementation of new informatics pipelines incorporating both innovative machine learning and traditional image processing algorithms into a Unix based cloud distributable pipeline leveraging best-in-class open source algorithms for the iNeuroRx^® platform. Mr. Alworth has been active in the SMA, ALS and FTD disease modeling fields since 2010. He led translational collaborations at Harvard University, with Nikon Corporation, and subsequently with co-founder Dr. Justin Ichida at USC. Mr. Alworth led the development of an AI enabled drug discovery software SVCell (which became Aivia) that was acquired by Leica. He has many issued and pending patents and scientific journal publications.